There is still time to fill out the MCQ and submit your essay for the prestigious PharmaTimes International Clinical Researcher of theYear competition – but with less than two weeks to go until entries close, you should start the process now.
News
Report calls for urgent action on R&D model
“Urgent action” is required to boost the productivity of the UK’s R&D model, which is grappling with “unprecedented pressure”, claims a new report by Medicines Discovery Catapult and the BioIndustry Association.
GPs dealing with ‘unsafe’ work load
GPs in the UK are dealing with an average of 41.5 patient contacts every day, which is 60 percent more than what is deemed safe by peers in Europe, an investigation by Pulse has revealed.
Research backs blanket screening for breast, ovarian cancer mutations
Research led by Queen Mary University of London has concluded that whole-population testing for mutations linked with a higher risk of breast and ovarian cancer is cost-effective.
Cabometyx trial halted early on success in liver cancer
A late-stage trial assessing Ipsen and Exelixis’ Cabometyx in advanced liver cancer has been halted early after a significant improvement in overall survival was observed.
Blood cancer care needs improving, finds MP inquiry
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
Speedy EU, US review for Novartis’ CAR-T therapy Kymriah
Regulators on both sides of the Atlantic are undertaking speedy reviews of Novartis’ CAR-T therapy Kymriah.
Pfizer asked to submit CDF proposal for Xalkori
Pfizer’s Xalkori has been turned away by the National Institute for Health and Care Excellence to treat ROS1-positive advanced non-small cell lung cancer.
NICE approves CDF funding for Janssen’s Darzalex
The National Institute for Health and Care Excellence (NICE) is backing NHS use of Janssen’s Darzalex via the Cancer Drugs Fund (CDF) for some adults with previously treated multiple myeloma.
Keytruda/chemo combo extends survival in NSCLC patients
A combination of MSD’s Keytruda and chemotherapy extended overall survival when used as a first-line treatment of patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Merck, CR UK, ICR collaborate on cancer drug discovery
Cancer Research UK’s Commercial Partnerships Team and The Institute of Cancer Research, London, have entered into a multi-project collaboration and licensing deal with Germany’s Merck to discover and develop new anticancer therapies.
Novartis’ Cosentyx beats J&J’s Stelara in psoriasis trial
Novartis has released trial data showing that Cosentyx was “significantly more effective” than Johnson & Johnson’s rival biologic Stelara in achieving clear skin in patients with psoriasis.
A&E pressures not down to GP access, study finds
The rising tide of accident and emergency attendances is being driven by long-term health conditions rather than a lack of GP provision, concludes a study by Queen Mary University of London.
Avacta, Glythera link to develop drug conjugates
UK companies Avacta and Glythera have sealed a licensing deal to develop drug conjugates using their combined technologies.
SMC bars four medicines from NHS
The Scottish Medicines Consortium has rejected NHS funding for four new therapies, including Bristol-Myers Squibb and Roche’s respective cancer medicines Opdivo and Gazyvaro.
